INNATE PHARMA (EPA:IPH) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
INNATE PHARMA

BRIEF

published on 11/28/2025 at 07:05, 6 days 22 hours ago

New number of shares and voting rights of Innate Pharma

Euronext Paris Share Capital Nasdaq Innate Pharma Shares And Rights
BRIEF

published on 11/17/2025 at 07:05, 17 days 22 hours ago

Innate Pharma to Present at Jefferies Global Healthcare Conference

Biotechnology Immunotherapy Innate Pharma Jefferies Conference Antibody Therapeutics
PRESS RELEASE

published on 11/17/2025 at 07:00, 17 days 22 hours ago

Inside Information / Other news releases
Innate Pharma to present at Jefferies Global Healthcare Conference on November 17, 2025. A global biotechnology company focusing on cancer immunotherapies

Biotechnology Immunotherapy Cancer Innate Pharma Jefferies Global Healthcare Conference
BRIEF

published on 10/14/2025 at 07:05, 1 month 21 days ago

Innate Pharma Highlights Lacutamab at Analyst and Investor Event

Investors Clinical Trial Innate Pharma Lacutamab Sézary Syndrome
PRESS RELEASE

published on 10/14/2025 at 07:00, 1 month 21 days ago

Inside Information / Other news releases
Innate Pharma to host analyst and investor event on Lacutamab on October 28, 2025. Event includes clinical perspectives, market outlook, and updates on Phase 3 trial and regulatory pathway for lacutamab

Phase 3 Trial Investor Event Regulatory Pathway Innate Pharma Lacutamab
BRIEF

published on 09/10/2025 at 10:35, 2 months 24 days ago

Innate Pharma Announces 2025 Half-Year Results Conference Call

Financial Results Conference Call Immunotherapy Innate Pharma Biopharmaceutical Partnerships
PRESS RELEASE

published on 09/10/2025 at 10:30, 2 months 24 days ago

Inside Information / Other news releases
Innate Pharma schedules conference call and webcast for first half 2025 financial results and business update. Details for participation available on the company's website

Financial Results Conference Call Business Update Webcast Innate Pharma
BRIEF

published on 09/02/2025 at 07:05, 3 months 2 days ago

Innate Pharma: Update on capital and voting rights

Voting Rights Real Estate Actions AMF Innate Pharma
PRESS RELEASE

published on 09/02/2025 at 07:00, 3 months 2 days ago

Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Innate Pharma releases the total number of shares (92,185,473 ordinary shares, 6,419 Preferred Shares 2016, 7,581 Preferred Shares 2017) and voting rights (92,962,943 theoretical, 92,944,368 exercisable) as of September 1, 2025 in compliance with regulations

Voting Rights Shares Stock Market Regulations Innate Pharma
BRIEF

published on 08/04/2025 at 07:05, 4 months ago

New number of shares and voting rights for Innate Pharma

AMF Financial Update Shares And Voting Rights Commercial Code Innate Pharma

1 2 ... 6

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 47 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 52 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 22 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 17 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 22 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 51 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 31 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 56 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 6 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 11 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 22 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 37 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 37 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 21 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE